As of September 30, cash, cash equivalents and available-for-sale securities were $111.9M, compared to $162.3M as of December 31, 2021. Based on its current operating and development plans, Decibel believes that its existing cash, cash equivalents and available-for-sale securities will fund its operating expenses into 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DBTX:
- Decibel Therapeutics announces submission of CTAs for DB-OTO
- H.C. Wainwright says ‘Decibel could certainly be acquired as well’ after Akouos
- Decibel has positive read through from Akouos takeover, says Baird
- Decibel Therapeutics receives FDA clearance of IND for DB-OTO
- Decibel Therapeutics appoints Kevin McLaughlin to Board